Prevalence of post-prostatectomy erectile dysfunction and a review of the recommended therapeutic modalities

Int J Impot Res. 2021 May;33(4):401-409. doi: 10.1038/s41443-020-00374-8. Epub 2020 Nov 17.

Abstract

Radical prostatectomy (RP) represents one of the most commonly used first-line treatment modalities in men with localized prostate cancer. One of the most feared post-surgical complications is erectile dysfunction (ED), usually caused by direct damage to the cavernous nerves or due to neuropraxia. Penile rehabilitation is an emerging concept that was proposed to stimulate and accelerate recovery of erectile function after RP. The goal is to improve blood flow to the penis, increasing cavernous oxygenation and avoiding fibrosis. The most common used modalities include oral phosphodiesterase type 5 inhibitors (PDE5-I), vacuum erection devices (VEDs), intracorporeal injection (ICI) therapy, medicated urethral system for erections (MUSE), and a combination of these treatments. For those patients with severe ED, ED refractory to medical therapy and/or seeking long term reliable results, the penile prosthesis implant remains an excellent alternative. We conducted a broad review of post-prostatectomy ED prevalence with different techniques and the success rates of the different therapeutic approaches.

Publication types

  • Review

MeSH terms

  • Erectile Dysfunction* / epidemiology
  • Erectile Dysfunction* / etiology
  • Erectile Dysfunction* / therapy
  • Humans
  • Male
  • Penile Erection
  • Phosphodiesterase 5 Inhibitors / therapeutic use
  • Prevalence
  • Prostatectomy / adverse effects
  • Prostatic Neoplasms* / surgery

Substances

  • Phosphodiesterase 5 Inhibitors